1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Gene Biotherapeutics, Inc.

Gene Biotherapeutics, Inc.

CRXM
Gene Biotherapeutics, Inc.US flagOther OTC
0.00
USD
+0.00
- -
6,493.00Market Cap
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
TTM
Revenue per Share
0.19
0.18
0.07
- -
0.01
0.02
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-10.94
-4.77
-1.28
-1.68
-1.41
-1.33
-0.5
-0.34
-0.28
-0.13
-0.03
0.06
- -
-0.03
Free Cash Flow per Basic Share
-8.14
-4.74
-2.02
-1.81
-1.56
-0.86
-0.24
-0.08
-0.16
-0.07
-0.03
-0.01
- -
-0.06
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-32.88
-31.12
-21.92
-20.71
-16.28
-15.06
-9.97
-8.91
-8.81
-8.35
-8.31
-8.21
- -
-6.64
Tangible Book Value per Share
-2.1
-0.88
1.74
1.12
0.87
0.17
-0.15
-0.3
-0.25
-0.36
-0.39
-0.33
- -
-0.25
Basic Weighted Avg Shares
2
2
4
4
6
7
11
13
13
14
14
14
- -
18
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-4,114.62
-1,958.2
-2,769.06
- -
-13,960.55
-6,324.4
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-25
-12
-5
-7
-8
-9
-6
-4
-3
-2
- -
1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-5,900.06
-2,625.14
-1,937.3
- -
-14,010.18
-8,163.27
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-2
-3
6
4
3
-1
-2
-4
-3
-5
-6
-5
-5
-5
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
-1
-2
7
6
6
1
-2
-4
-3
-5
-6
-5
-5
-5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.84
- -
-2.89
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
31
40
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Jun'20
Sep'20
Dec'20
Total Current Assets
1
1
- -
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
5
5
Payables & Accruals
4
4
4
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-17.82%
6.59%
-5.81%
Free Cash Flow
53.04%
131.66%
728.54%
Net Income, GAAP
-58.9%
-118.45%
-159.76%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
-0.03
2019
-0.02
-0.02
-0.01
- -
0.06
2020
-0.01
0.03
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2018
- -
- -
- -
- -
- -
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Christopher J. Reinhard
Full Time Employees
3
Sector
Healthcare
Industry
Biotechnology
Address
11230 Sorrento Valley Road San Diego CA United States of America 92121
IPO Date
May 3, 2000
CIK
0000772320
Website
genebiotherapeutics.com
Similar Companies
Genovis AB (publ.) (GENO.ST)
Histogen Inc. (HSTO)
Hcmed (6934.TWO)
Bellicum Pharmaceuticals, Inc. (BLCM)
OncoTherapy Science, Inc. (4564.T)
GeneOne Life Science, Inc. (011000.KS)
Business
Gene Biotherapeutics, Inc. (CRXM) is a clinical-stage biotechnology company focused on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases, particularly myocardial ischemia and refractory angina due to advanced coronary artery disease. The company's lead product candidate, Generx (Ad5FGF-4), is an investigational angiogenic gene therapy in Phase 3 clinical trials under the AFFIRM study; Generx utilizes a replication-deficient adenovirus serotype 5 vector to deliver the human fibroblast growth factor-4 (FGF-4) gene, promoting microvascular growth in ischemic cardiac tissue via a one-time administration during an angiogram-like procedure by interventional cardiologists. It also advances Generx for ischemia-related cardiovascular and cerebral indications, including cardiac microvascular insufficiency, cardiac syndrome X, congestive heart failure, moyamoya disease, and cerebral ischemia; the company pursues advanced tissue engineering applications through its gene therapy platform. Gene Biotherapeutics maintains a manufacturing agreement with Fujifilm Diosynth Biotechnologies for Phase 3 clinical and commercial-scale GMP production of Generx at facilities in College Station, Texas. Founded in 2003 and headquartered at 11230 Sorrento Valley Road, Suite 220, San Diego, California, the company operates primarily in the United States as an 80%-owned operating unit and subsidiary of Nostrum Pharmaceuticals, LLC; it previously operated as Taxus Cardium Pharmaceuticals Group, Inc. until renaming in January 2018. Recent developments include ongoing advancement of the Phase 3 AFFIRM trial for Generx and retention of commercialization rights following the sale of its Excellagen technology platform to Olaregen Therapeutix Inc.